Vanguard Group
DERM icon

Vanguard Group’s Journey Medical DERM Stock Holding History

Vanguard Group’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$5.89M Buy
764,147
+148,918
+24% +$1.17M ﹤0.01% 3189
2025
Q3 		$4.38M Buy
615,229
+50,241
+9% +$364K ﹤0.01% 3322
2025
Q2 		$4.06M Buy
564,988
+192,727
+52% +$1.33M ﹤0.01% 3286
2025
Q1 		$2.2M Buy
372,261
+47,090
+14% +$232K ﹤0.01% 3467
2024
Q4 		$1.27M Hold
325,171
– – ﹤0.01% 3690
2024
Q3 		$1.84M Buy
325,171
+14,923
+5% +$76.8K ﹤0.01% 3586
2024
Q2 		$1.75M Hold
310,248
– – ﹤0.01% 3599
2024
Q1 		$1.14M Buy
310,248
+180,800
+140% +$787K ﹤0.01% 3766
2023
Q4 		$746K Buy
129,448
+56,781
+78% +$253K ﹤0.01% 3915
2023
Q3 		$199K Buy
72,667
+51,634
+245% +$115K ﹤0.01% 4252
2023
Q2 		$33.4K Buy
21,033
+1
+0% +$2 ﹤0.01% 4497
2023
Q1 		$33K Buy
21,032
+4,083
+24% +$7.61K ﹤0.01% 4501
2022
Q4 		$32.5K Buy
16,949
+106
+0.6% +$210 ﹤0.01% 4473
2022
Q3 		$41K Buy
16,843
+6,408
+61% +$21.8K ﹤0.01% 4562
2022
Q2 		$39K Buy
+10,435
New +$41.3K ﹤0.01% 4597

Other funds holding DERM

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group's DERM Position: Q4 2025 in Review

Vanguard Group increased its Journey Medical (DERM) stake by 24% in Q4 2025, buying an estimated $1.17M and bringing the position to 764,147 shares worth $5.89M. The position accounts for ﹤0.01% of the portfolio, ranked #3189.

Vanguard Group first reported a position in DERM in Q2 2022 and has held it in 15 quarters since. 77 funds tracked by Wall St. Rank hold DERM as of Q4 2025.

  • Vanguard Group held 764,147 shares of Journey Medical worth $5.89M as of Q4 2025.
  • Vanguard Group bought 148,918 Journey Medical shares in Q4 2025, an estimated $1.17M.
  • Journey Medical made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3189 holding.
  • Vanguard Group first reported a position in Journey Medical in Q2 2022 and has held it in 15 quarters since.
  • 77 funds tracked by Wall St. Rank held Journey Medical as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.